Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Free Trade Agreements May Impede Supply Of AIDS Drugs From India, Says Study

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Regional and bilateral free trade agreements may seriously threaten future supplies of life-saving antiretroviral drugs from Indian companies, warned Geneva-based UNITAID - the agency that facilitates access to low-cost medicines in developing countries

You may also be interested in...



Indian Pharma Lobby Flays India-EU Trade Talks; Debunks "TRIPS Plus" Provisions On Patent Extensions And Data Protection

MUMBAI - Hardball negotiations between Indian and European Union representatives on the signing of a free trade agreement may lead to flare ups after the Indian Pharmaceutical Alliance - a powerful industry lobby - raised strong objections on provisions related to intellectual property rights that are sought to be incorporated in the draft treaty

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

SC075924

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel